NCT06975319View on ClinicalTrials.gov

Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

December 2, 2025

Study Completion Date

July 30, 2026

Conditions
HealthyImmunisation Against Streptococcus Pneumoniae
Interventions
BIOLOGICAL

V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose

V-212 is a peptide antigen-based vaccine.

BIOLOGICAL

V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose

V-212 is a peptide antigen-based vaccine.

BIOLOGICAL

V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose

V-212 is a peptide antigen-based vaccine.

Trial Locations (1)

9000

Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent

Sponsors

Lead Sponsor

Virometix

Collaborators (1)

CR2O
All Listed Sponsors
collaborator

CR2O

UNKNOWN

lead

Virometix

INDUSTRY

NCT06975319 - Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter